About Penta
Who we are
Diversity and Inclusion
Our Network
Penta Foundation Italy
Penta ID Innovation
Annual reports
Our Activities
News & Events
News
Press center
Penta Newsletter
Stories
Scientific Views
Penta Aperitivo Webinars
Publications
Contact us
Work with us
Vacancies
Calls for service
PentaTr@ining
Archivio
Once daily integrase inhibitor (INSTI) with boosted darunavir is non-inferior to standard of care in virologically suppressed children – Week 48 results of the SMILE Penta-17 Trial
Once-Daily Integrase Inhibitor (Insti) With Boosted Darunavir is Non- Inferior to Standard of Care in Virogically Suppressed Children, Week 48 Results of the SMILE PENTA-17 Trial
New findings from the ODYSSEY trial confirm superiority of dolutegravir-based ART in younger children – A story by WHO
Measuring research capacity development in healthcare workers: a systematic review
Penta at IAS and the International Workshop on HIV Pediatrics 2021
Left ventricular longitudinal strain alterations in asymptomatic or mildly symptomatic paediatric patients with SARS-CoV-2 infection
Early ART initiation during infancy preserves natural killer cells in young European adolescents living with HIV (CARMA cohort)
Penta at ECCMID 2021
🇬🇧 New data on the duration of immune protection against SARS-CoV- 2 in children
Penta in 2020
Mild SARS-CoV-2 infections and neutralizing antibody titers